摘要
目的探究重组人干扰素α1b联合氨溴索治疗小儿支气管肺炎的临床效果及对血清转化生长因子β_(1)(TGF-β_(1))、C反应蛋白(CRP)水平的影响。方法纳入99例小儿支气管肺炎患儿,并以随机数字表法分成观察组与对照组,对照组(50例)采用常规对症治疗+氨溴索静滴治疗,观察组(49例)在对照组治疗的基础上联合重组人干扰素α1b雾化吸入治疗,比较2组患儿的临床治疗效果、治疗前后患儿TGF-β_(1)及CRP水平变化、患儿症状消失时间(发热、咳嗽、气促、肺部啰音等)、治疗前后患儿血氧饱和度变化及肺功能指标变化和不良反应。结果观察组患儿治疗总有效率(95.92%)较对照组(84.00%)更高,P<0.05;治疗前,2组患儿TGF-β_(1)及CRP水平、血氧饱和度、最大呼气压(PE_(max))、最大吸气压(PI_(max))、呼气峰流速(PEF)及用力肺活量(FVC)等肺功能指标比较差异无统计学意义(P>0.05)。治疗后2组患儿TGF-β_(1)及CRP水平、血氧饱和度、PE_(max)、PI_(max)、PEF和FVC等指标均改善,且观察组以上指标均优于对照组,P<0.05;观察组患儿症状(发热、咳嗽、气促、肺部啰音等)消失时间较对照组均更短,P<0.05;2组患儿不良反应率均较低,观察组为4.08%,对照组为4.00%,P>0.05。结论重组人干扰素α1b联合氨溴索治疗小儿支气管肺炎临床疗效显著,可较好降低患儿的TGF-β_(1)及CRP水平,从而缓解患儿的症状,促进患儿康复,且安全可靠。
Objective To investigate the clinical effect of recombinant human interferonα1b combined with ambroxol in the treatment of children with bronchial pneumonia,and the effect on serum transforming growth factorβ_(1)(TGF-β_(1))and C-reactive protein(CRP)levels.Methods A total of 99 children with bronchial pneumonia were included in this study,and were divided into observation group and control group by random number table method.The control group(50 cases)received conventional symptomatic treatment+ambroxol intravenous drops treatment,while the observation group(49 cases)received aerosol inhalation treatment combined with recombinant human interferonα1b on the basis of treatment in the control group.The clinical treatment effects,the changes in TGF-β_(1) and CRP levels before and after treatment,the time of symptom resolution(fever,cough,shortness of breath,lung rales,etc.),the changes in blood oxygen saturation,the changes in lung function indexes,and adverse reactions were compared before and after treatment.Results Compared with the control group(84.00%),the total effective rate of observation group(95.92%)was higher,P<0.05.There was no signifiant difference in the levels of TGF-β_(1) and CRP,oxygen saturation,maximum expiratory pressure(PE_(max))and_(max)imum inspiratory pressure(PI_(max)),peak expiratory flow rate(PEF)and forced vital capacity(FVC)between the 2 groups before treatment(P>0.05).The TGF-β_(1) and CRP levels,blood oxygen saturation,PE_(max),PI_(max),PEF and FVC were all improved in each group after treatment.The TGF-β_(1) and CRP levels,blood oxygen saturation,PE_(max),PI_(max),PEF and FVC were better in the observation group after treatment than those in the control group(P<0.05).Compared with the control group,the time of symptom disappearance(fever,cough,shortness of breath,lung rales,etc.)in the observation group was shorter(P<0.05).The adverse reaction rate of the 2 groups was low,the observation group was 4.08%,and the control group was 4.00%,P>0.05.Conclusion Recombinant human interferonα1b combined with ambroxol in the treatment of children with bronchial pneumonia has a significant clinical effect,which can better reduce the levels of TGF-β_(1) and CRP in children,so as to alleviate the symptoms patiens,promote the recovery of patiens.The combination is safe and reliable.
作者
屈云娜
冉彩萍
黄婉婷
王鑫
QU Yunna;RAN Caiping;HUANG Wanting;WANG Xin(Department of Pediatrics,the Second People s Hospital of Xining City,Xining 810000,China;Department of Pediatrics,Qinghai Maternal and Child Health Hospital,Xining 810000,China)
出处
《西北药学杂志》
CAS
2022年第6期129-132,共4页
Northwest Pharmaceutical Journal
基金
青海省科技计划项目(编号:2019-ZJ-7089)。
